Conivaptan Hydrochloride Injection Shortage: Current Availability and Shipping Updates
The FDA reports a current shortage of Conivaptan Hydrochloride Injection due to shipping delays, with Cumberland Pharmaceuticals Inc. reporting its supply as unavailable.
What’s in Shortage
Conivaptan Hydrochloride Injection is currently listed in a shortage status. This medication is categorized under the Cardiovascular therapeutic category and is provided in an injection dosage form.
Which Manufacturers Are Affected
The following manufacturer is currently impacted by this shortage:
- Cumberland Pharmaceuticals Inc.
- Availability: Unavailable
- Presentation: Vaprisol Dextrose In Plastic Container, Injection, 20 mg/100 mL (NDC 66220-160-10)
- Contact Information: 615-255-0068
Why There’s a Shortage
The current reason provided for the shortage of Conivaptan Hydrochloride Injection is a delay in shipping of the drug.
What Patients Should Do
Patients who may be affected by this shortage should take the following steps:
- Consult Your Healthcare Provider: Patients should consult their healthcare provider regarding their treatment and to discuss any potential clinical alternatives. This article does not provide medical advice.
- Speak with a Pharmacist: Contact your pharmacist to check on current stock levels and local availability.
- Contact the Manufacturer: For specific questions regarding supply, you may contact Cumberland Pharmaceuticals Inc. directly at 615-255-0068.
Source
This information is based on data from the FDA Drug Shortage Database.
- Initial Posting Date: 03/14/2022
- Last Updated: 03/16/2026
Source: FDA Official Notice
Related Articles
Promethazine Hydrochloride Injection Shortage: Current Status and Manufacturer Updates
FDA · March 21, 2026
Cefotaxime Sodium Powder for Solution Shortage: Current Status and Manufacturer Updates
FDA · March 21, 2026
Desmopressin Acetate Spray Shortage: Current Supply Updates and Manufacturer Status
FDA · March 5, 2026